Skip to content
AnalystLens

Exelixis Annual Report, Year Ended Dec 31, 2021

Filing Date
Filed February 18, 2022
Period End
December 31, 2021
Security
EXEL
In the record · 2016–202610-K1110-Q358-K119

EXEL filed 11 annual reports (10-K), 35 quarterly reports (10-Q) and 119 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Leadership change8-K · Mar ’21Mar ’21
  3. Leadership change8-K · May ’26May ’26

Summary

Summary of the 10-K filed February 18, 2022. Cited figures are marked; the original filing is the authoritative source.

Exelixis, Inc. (Exelixis) reported its fifth consecutive year of profitability for 2021, with net income of $231.1 milliona ($0.72 per diluted share) compared with $111.8 million in 2020, and total revenues of $1,435.0 million, up from $987.5 million.

Net product revenues were $1,077.3 millionb, driven mainly by CABOMETYX (cabozantinib), which generated $1,054.1 million, a 42% increase in units sold that the filing attributes largely to uptake of the CABOMETYX plus OPDIVO first-line RCC combination approved by the FDA in January 2021. Cash and investments rose to $1.9 billion at December 31, 2021, from $1.5 billion a year earlier. The company's near-term value depends heavily on CABOMETYX.

The filing flags generic competition: MSN and Teva have filed ANDAs seeking to market generic versions, and Exelixis has sued both. A bench trial against MSN is scheduled for May 2022, and the Teva case has been stayed. The filing states that approval of either ANDA could significantly decrease U.S. CABOMETYX revenues.

Royalty income from partners Ipsen and Takeda also grew, and the company expects license revenues to decline in 2022 because fewer milestones are anticipated. Pipeline catalysts for 2022 include top-line COSMIC-313 results in the first half, the final overall survival analysis of COSMIC-312 in the first quarter (the company intends to file an sNDA if supported), interim OS results from CONTACT-01 in the second half, and the planned start of Phase 3 STELLAR-303 for XL092. Management projects higher R&D and SG&A spending and higher 2022 net product revenues.

Key Highlights

  1. Total revenues rose to $1,434,970 thousand in 2021 from $987,538 thousand in 2020; net income was $231,063 thousand ($0.72 diluted EPS), up from $111,781 thousand.
  2. Net product revenues were $1,077,256 thousand; CABOMETYX contributed $1,054,050 thousand, and the filing attributes a 42% increase in CABOMETYX units sold mainly to the CABOMETYX plus OPDIVO combination approval.
  3. Cash, cash equivalents, restricted cash equivalents and investments were $1,854,908 thousand at December 31, 2021, up from $1,538,842 thousand.
  4. Generic exposure: MSN and Teva filed ANDAs for generic CABOMETYX; the filing says approval of either could significantly decrease U.S. CABOMETYX revenues, and a bench trial against MSN is scheduled for May 2022.
  5. Ipsen royalty revenues were $97.2 million in 2021 versus $76.2 million in 2020; the company expects royalty growth to partly offset fewer milestones, so license revenues are projected to decline in 2022.
  6. Key 2022 catalysts include COSMIC-313 top-line results (first half), the final OS analysis of COSMIC-312 (Q1 2022), and CONTACT-01 interim OS results (second half 2022).
  7. Management projects 2022 net product revenue growth, with R&D and SG&A expenses expected to increase; the effective tax rate is projected at 20% to 22%.

Frequently Asked Questions

  1. How dependent is Exelixis on CABOMETYX?

    Very dependent. The filing says sales related to cabozantinib account for the large majority of revenues, and CABOMETYX generated $1,054.1 million of the $1,077.3 million in 2021 net product revenues. Management states its ability to generate cash flow depends on CABOMETYX's continued commercial success.

  2. What is the main threat to CABOMETYX revenue?

    Generic competition. MSN and Teva have each submitted ANDAs for generic CABOMETYX tablets. Exelixis has sued both over patent infringement, and the filing says a generic approval before patent expiry could significantly reduce U.S. CABOMETYX revenues. The composition-of-matter patent is listed as expiring in 2026, with later-expiring listed patents running to 2037.

  3. Why did product revenues grow in 2021?

    The filing attributes most of the 45% growth in net product revenues to a 42% increase in CABOMETYX units sold, driven mainly by strong uptake of the first-line combination with OPDIVO after the January 2021 FDA approval. It also cites a 3% increase in average net selling price, plus higher royalties from Ipsen and Takeda.

  4. What should investors watch in 2022?

    Several readouts are expected in 2022: COSMIC-313 top-line results (first half), the final OS analysis for COSMIC-312 (Q1 2022), and CONTACT-01 interim OS (second half). The company also plans to start the Phase 3 STELLAR-303 trial for XL092 in the first half of 2022 and expects to advance up to five new development candidates to preclinical development.

  5. Does the company expect license revenue to keep growing?

    Not in 2022. The filing projects license revenues may decrease in fiscal 2022 because fewer milestones are expected, partly offset by higher royalties from Ipsen and Takeda. Collaboration services revenues are also projected to fall, since 2021 included a $43.2 million cumulative catch-up tied to Ipsen's COSMIC-311 cost sharing.